Dudani S, Graham J, Wells JC, et al. - Using the International Metastatic Renal-cell Carcinoma Database Consortium dataset, researchers contrasted the efficiency of ipi-nivo vs immuno-oncology (IO)-vascular endothelial growth factor (VEGF)(IOVE) combinations in metastatic renal-cell carcinoma, and explain practice patterns and efficacy of second-line therapies in 113 patients who received IOVE combinations and 75 who received ipi-nivo. No notable variations in first-line outcomes between IOVE combinations and ipi-nivo were found. In the second line, most patients were receiving VEGF-based therapy. In patients who received ipi-nivo initially, the second-line response rate was greater in this group.